Curated gurus reporting this holding
A curated subset of well-known investors — not the full institutional ownership.
- Duquesne Family Office203,618주2026-06-30
Rhythm Pharmaceuticals company information
리듬 파머슈티컬스NASDAQ:RYTM · Nasdaq · Healthcare$92.83-0.62%
2026-10-02 closeRhythm Pharmaceuticals's company information is shown as of 2026-10-02. It is a security listed on Nasdaq, ticker RYTM. There are 14 published related companies.
About this company
Rhythm Pharmaceuticals last closed at $92.83 (-0.62%) on 2026-10-02. Listed on Nasdaq.
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F is quarterly and may be filed up to 45 days later.
Suppliers, competitors and related stocks
- AmgenCompetitor
비만·희귀질환 치료제 개발 경쟁사
- Novo NordiskCompetitor
비만 치료제 시장의 핵심 경쟁사
- Eli LillyCompetitor
비만 치료제 분야의 가장 큰 경쟁사
- IpsenCompetitor
희귀질환·내분비 치료제 영역의 경쟁사
- PfizerCompetitor
희귀질환 치료제 및 대사질환 파이프라인 경쟁사
- Ascendis PharmaCompetitor
희귀 내분비 질환 치료제 경쟁사
- Healthcare providersCustomer
병원·전문의가 처방하는 희귀질환 치료제의 주요 채널
- PayersCustomer
보험사·약제급여기관이 약가와 접근성을 좌우하는 주요 고객
- Endocrinology specialistsCustomer
비만유전질환 환자를 진단·치료하는 핵심 처방 의료진
- Rare diseaseRelated theme
희귀질환 치료제 개발·상업화 테마
- ObesityRelated theme
비만 치료제 및 체중조절 관련 제약 테마
- Metabolic disordersRelated theme
대사질환 치료제 시장과 직접 연관된 테마
- GeneticsRelated theme
유전성 비만·희귀질환 원인 규명과 치료 타깃 발굴과 연관
- EndocrinologyRelated theme
내분비계 질환 치료와 진단을 둘러싼 핵심 의료 테마
Major stocks in the same sector
2026-10-04 dataset
📦 ETFs holding this stock
by weight · top-10 constituents basisPassive money holding this stock ≈ $2M(lower bound — top-10 basis, not a forecast)
Factual holdings info from daily disclosures — not a recommendation.
Look up another stock →Quantus Signal · live data · not investment advice · Privacy Policy